Literature DB >> 27751562

[Unexplained recurrent early miscarriages: Role of immunomodulation?]

A Mekinian1, J Cohen2, G Kayem3, L Carbillon4, P Nicaise-Roland5, B Gaugler6, E Darai2, M Bornes2, O Fain7.   

Abstract

About 1-3% of women experience early recurrent miscarriages, defined by ≥3 fetal loss before 14 weeks of gestation. About half of these recurrent early miscarriages could be related to a genetic cause. Pre-implantation genetic diagnosis is used in several European countries, but it is still prohibited in France except for couples at risk for transmission of severe genetic diseases. The immune dysregulation, and in particular allo-immune excessive response, could be responsible for fetal loss in remaining cases, although currently we lack biomarker to confirm the immune-mediated fetal loss. Several immunosuppressive and immunomodulatory treatments have been the subject of small studies in patients with early recurrent miscarriages. The available data do not allow to define the treatment recommendations in this topic, and further studies are necessary.
Copyright © 2016 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Biological-targeted agents; Biothérapies; Fausses couches inexpliquées; Immunomodulation; Unexplained recurrent early miscarriages

Mesh:

Substances:

Year:  2016        PMID: 27751562     DOI: 10.1016/j.revmed.2016.08.001

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  2 in total

1.  The association of AT-III and D-Dimer with unexplained recurrent spontaneous abortion and their diagnostic value for prethrombotic state.

Authors:  Minhuan Ye; Runyi Fang; Simin Lun; Jianhua Fang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

2.  The Efficacy and Safety of the Zhuyun Formula and Auricular Acupressure for the Infertile Women with Recurrent Implantation Failure: A Randomized Controlled Trial.

Authors:  Hang Zhou; Xiaoyan Zheng; Wanting Xia; Qianhong Ma; Jinmei Li; Qian Zeng; Jinzhu Huang
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-11       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.